<DOC>
	<DOC>NCT00207168</DOC>
	<brief_summary>To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.</brief_summary>
	<brief_title>To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine</brief_title>
	<detailed_description />
	<criteria>18 or older, required lab results, currently taking no more than two of the proposed once daily arm medications with medications administered twice daily and women of child bearing potential. virological failure, serious medical condition, known toxicities to any of the once daily arm medications, lab abnormalities, women who are pregnant/breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
</DOC>